Regencell Corp - חוב לטווח קצר של החברה RGC

Regencell Bioscience aims to capture the autism and ADHD therapy niche by implementing Chinese medicine methods. However, trade wars between the US and China are hindering the exchange of biodata and joint research. GURU.Markets analytics includes this chart of short-term debt book value with a metric value of 0.00. There is a high probability that funds will be exhausted before the product reaches the market.

Investors are assessing the financial stability of Regencell Bioscience (RGC) through its current liabilities, which measure the current debt load and the business's ability to service its loans. By analyzing the volume of short-term liabilities, one can determine how effectively the company is financing the early stages of developing plant-based treatments for ADHD while avoiding critical liquidity shortages within a niche market.